GLOBALLY CONNECTED MEDICINAL CANNABIS GROUP
Health House Holdings Limited was founded to pursue opportunities in the burgeoning global medicinal cannabis market.
Since 2014, the Board and founding shareholders of the Company have been pioneers in the Global medicinal cannabis sector establishing a number of publicly-listed companies including AusCann Group, Zelda Therapeutics and CannPal Animal Therapeutics.
Premium Quality Range – Products to view full range of products.
HAPA pharm is an internationally operating German company with the focus on the development, production and distribution of cannabinoid containing products.The company stands for a controlled cultivation of cannabis plants in Europe as well as for their own production of suitable products according to GMP guidelines.
Every Satipharm CBD capsule is powered by Gelpell® technology which is clinically proven to increase the bioavailability of CBD. This is based on their clinical trial and the use of Gelpell® Microgel Capsule technology, which was developed and manufactured in Switzerland. By using Satipharm CBD capsules, patients can be confident they will receive the same dose every time.
iX Biopharma launched Xativa™, the world’s first medicinal cannabis sublingual wafer made in Australia and formulated using WaferiX™, their patented sublingual delivery technology. Each wafer contains a nano-emulsion of highly bioavailable broad-spectrum cannabis extract in addition to 30+ terpenes and other beneficial molecules naturally occurring in cannabis.
Australian Natural Therapeutics Group (ANTG) is Australia’s first GACP & GMP accredited medicinal flower cultivation and manufacturing facility. It is Australian grown and made, cultivated in NSW, with all natural, renewable medium, without harmful pesticides. ANTG’s aim is for all Australians to benefit from high-quality, affordable and locally produced medicines.
Little Green Pharma was the first medical cannabis company in Australia to produce locally grown medical-grade cannabis products. Their medicinal cannabis products include a range of oils tested to stringent Australian quality standards. Little Green Pharma also works closely with medical practitioners to assist them with applications for medical cannabis products; saving patients time and money.
Health House currently distributes ZENIVOL™, part of a growing family of proprietary cannabinoid-based medicines produced by ZELIRA Therapeutics. ZELIRA’s customised medicines are uniquely formulated and created by extracting, isolating, and then reassembling the medicinal compounds from the cannabis plant (including cannabinoids and terpenes) to achieve speciﬁc and targeted effects.
Ananda Hemp offers high-quality products made with full spectrum CBD oil extracted from 100% Kentucky-grown hemp. Every plant that goes into their high-end line of CBD products is cultivated using organic farming practices. They also contain an array of cannabinoids and hundreds of bioactive phytonutrients from the hemp – resulting in a formula that is truly deserving of the title ‘full spectrum’.
Cronos Australia offers premium quality Australian formulated cannabinoid-based medicines, ensuring a reliable supply chain and affordable pricing to improve patient access. The Adaya range of C02 extracted oral formulations offer patients a range of purified CBD and THC medicines. Cultivated Adaya Whole Flower products are rich in phytocannabinoids and therapeutic terpenoids.
Medigrowth is an Australian medicinal cannabis biotech with multi-disciplinary research involvement spanning plant science & next-gen technologies in biomedical analysis. Medigrowth is driven by a deep passion to improve quality of life for Australian patients. Industry partnership and University-led Australian Research Council Initiatives ensures Medigrowth continues the commitment to development and discovery.
LEVIN is a Melbourne-based medical cannabis company that aspires to develop cannabis-based medicines for patients suffering from chronic pain and other sports related conditions. LEVIN’s mission is to develop medicinal cannabis products backed by clinical evidence. They are committed to developing and providing the best cannabis-based sports medicine possible, made by Australians, for Australians.
Timeline: Towards a Legal Medicinal Cannabis Market
California passes Proposition 215. It becomes the first US state to legalise medicinal cannabis.
Portugal decriminalises the use of all drugs.
Canada passes the Medicinal Marijuana Access Program, which allows clinicians to prescribe medicinal cannabis.
Montana becomes tenth US state to legalise medicinal cannabis.
Israel approves the first government sanctioned cannabis growing operations.
Colorado & Washington
Colorado and Washington become the first two states to legalise the recreational use of cannabis.
UK-based GW Pharmaceuticals, listed on the AIM London market, dual lists on the US NASDAQ.
Canada introduces the Medical Purposes Regulations, which lets patients access the drug from licensed producers.
The Italian parliament signs a motion to legalise cannabis.
Canopy Growth becomes the first cannabis stock to list on the Toronto Stock Exchange.
Germany passes a law legalising the use of cannabis for medical purposes.
Israel announces it will exports of medicinal cannabis.
Sativa becomes the UK’s first medical cannabis investment vehicle to be listed on the NEX Exchange.
Poland votes in favour of legalising medicinal cannabis.
Canada’s Aurora Cannabis and CanniMed Therapeutics $3.2 billion merger becomes the industry’s biggest M&A deal.
Canada’s Cronos Group becomes the first cannabis company to list on the US NASDAQ.
UK Home Secretary Sajid Javid changes the classification of medicinal cannabis to Schedule 2.
Medicinal cannabis available on prescription in the UK.